scholarly journals Genome Sequence of a Genotype 2 Hepatitis E Virus World Health Organization Reference Strain

2017 ◽  
Vol 5 (7) ◽  
Author(s):  
Marco Kaiser ◽  
Saleem Kamili ◽  
Tonya Hayden ◽  
Johannes Blümel ◽  
Sally A. Baylis

ABSTRACT We report here the sequence of a genotype 2a reference strain of hepatitis E virus (HEV), developed on behalf of the World Health Organization. The HEV reference strain is intended for use in assays based on nucleic acid amplification for the validation of HEV RNA detection.

2018 ◽  
Vol 6 (16) ◽  
pp. e00292-18 ◽  
Author(s):  
Marco Kaiser ◽  
Déborah Delaune ◽  
Olivier Chazouillères ◽  
Johannes Blümel ◽  
Anne-Marie Roque-Afonso ◽  
...  

ABSTRACT We report here the genome sequence of a hepatitis E virus (HEV) strain from a chronically infected immunodeficient patient. Full-length sequence analysis revealed a distinct HEV strain, of a tentative new subgenotype, clustering with viruses from rabbits. It is a World Health Organization reference strain for validation of nucleic acid testing.


2013 ◽  
Vol 19 (5) ◽  
pp. 729-735 ◽  
Author(s):  
Sally A. Baylis ◽  
Johannes Blümel ◽  
Saeko Mizusawa ◽  
Keiji Matsubayashi ◽  
Hidekatsu Sakata ◽  
...  

2017 ◽  
Vol 55 (5) ◽  
pp. 1478-1487 ◽  
Author(s):  
Jeffrey J. Germer ◽  
Irina Ankoudinova ◽  
Yevgeniy S. Belousov ◽  
Walt Mahoney ◽  
Chen Dong ◽  
...  

ABSTRACT Hepatitis E virus (HEV) has emerged as a cause of chronic hepatitis among immunocompromised patients. Molecular assays have become important tools for the diagnosis and management of these chronically infected patients. A real-time reverse transcription-quantitative PCR (RT-qPCR) assay utilizing Pleiades probe chemistry and an RNA internal control for the simultaneous detection and quantification of HEV RNA in human serum was developed based on an adaptation of a previously described and broadly reactive primer set targeting the overlapping open reading frame 2/3 (ORF2/3) nucleotide sequence of HEV. A chimeric bovine viral diarrhea virus construct containing an HEV RNA insert (SynTura HEV) was developed, value assigned with the first World Health Organization (WHO) international standard for HEV RNA (code 6329/10), and used to prepare working assay calibrators and controls, which supported an assay quantification range of 100 to 5,000,000 IU/ml. The analytical sensitivity (95% detection rate) of this assay was 25.2 IU/ml (95% confidence interval [CI], 19.2 to 44.1 IU/ml). The assay successfully amplified 16 different HEV sequences with significant nucleotide mismatching in primer/probe binding regions, while evaluation of a WHO international reference panel for HEV genotypes (code 8578/13) showed viral load results falling within the result ranges generated by WHO collaborative study participants for all panel members (genotypes 1 to 4). Broadly reactive RT-qPCR primers targeting HEV ORF2/3 were successfully adapted for use in an assay based on Pleiades probe chemistry. The availability of secondary standards calibrated to the WHO HEV international standard can improve the standardization and performance of assays for the detection and quantification of HEV RNA.


2016 ◽  
Vol 4 (5) ◽  
Author(s):  
Jan-Hendrik Trösemeier ◽  
Didier Musso ◽  
Johannes Blümel ◽  
Julien Thézé ◽  
Oliver G. Pybus ◽  
...  

We report here the sequence of a candidate reference strain of Zika virus (ZIKV) developed on behalf of the World Health Organization (WHO). The ZIKV reference strain is intended for use in nucleic acid amplification (NAT)-based assays for the detection and quantification of ZIKV RNA.


2014 ◽  
Vol 1 (3) ◽  
Author(s):  
Kenrad E. Nelson ◽  
James W. K. Shih ◽  
Jun Zhang ◽  
Qinjian Zhao ◽  
Ningshao Xia ◽  
...  

Abstract Recurrent, large, waterborne epidemics of hepatitis E virus (HEV) occur regularly after monsoon rains contaminate water supplies in Asia or during humanitarian crises in Africa. These epidemics commonly affect thousands of persons, and it has a high mortality in pregnant women who become infected. Although a subunit HEV vaccine has been developed by Chinese investigators and was found to be highly effective and safe in a large clinical trial, this vaccine is only available in China. Until it is prequalified by the World Health Organization, the vaccine may not be available for use outside of China in low-income countries that lack national vaccine regulatory agencies. In this manuscript, we explore possible strategies for providing access to this potentially important vaccine for international use in responding to epidemics of HEV in low-resource countries.


Author(s):  
Mahnoor Patel

Global pandemic cause by coronavirus has been reported in Wuhan, China; in late December 2019. Within time duration of few weeks, the newly identified virus designated as 2019-Novel Coronavirus (2019-nCoV) and it was declared by World Health Organization (WHO). At the time of late January 2020, WHO announced it as the international emergency outbreak because of the rapid spread and increases at the global level. There is no any preventive vaccine is present or any approved therapy/treatment for this viral emergency which is very infectious globally. Till the previous few decades, six strains of coronaviruses were found, but in Wuhan, China in December 2019, a totally new strain of coronavirus was spread across the city. Within few days, it was designated as the novel coronavirus abbreviated as 2019-nCoV by World Health Organization. The rate of virus progression is still not determined and that is why it is very difficult to find the patient zero which is very essential. Phylogenetic analysis of the virus specifies bat origin of 2019-nCoV, its transmission is airborne i.e. human to human, infected person can be identified having the primary symptoms which includes high fever, upper or lower respiratory tract infection. Its diagnosis at the molecular level includes Real-Time PCR for encoding genes for the internal transcribed RNA-dependent RNA polymerase and Spike protein receptor binding domain. It can be confirmed by the Sanger Sequencing including full genome analysis by Next Generation Sequencing, multiplex nucleic acid amplification and microarray based analysis. There are few mRNA vaccines which were developed by few Biotechnology companies, showing positive results against COVID-19 and it is there in 4th phase clinical trial which possibly be the first vaccine available in the market in between mid-2021.


Sign in / Sign up

Export Citation Format

Share Document